Craig-Hallum Remains a Buy on scPharmaceuticals (SCPH)

Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on scPharmaceuticals (SCPH – Research Report) today. The company’s shares closed yesterday at $4.50.

Knickerbocker covers the Healthcare sector, focusing on stocks such as Xtant Medical Holdings, Fennec Pharmaceuticals, and Avadel Pharmaceuticals. According to TipRanks, Knickerbocker has an average return of 2.7% and a 48.53% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for scPharmaceuticals with a $21.25 average price target.

Based on scPharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $6.1 million and a GAAP net loss of $13.81 million. In comparison, last year the company earned a revenue of $34 thousand and had a GAAP net loss of $9.25 million

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

scPharmaceuticals (SCPH) Company Description:

scPharmaceuticals, Inc.engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.